Aptamer Group PLC on Thursday said it has partnered with Kairos Biotech Ltd for Optimer+ transplant rejection therapies.

As part of the partnership deal, the York, England-based biotechnology firm said that Kairos Biotech will ‘leverage Aptamer’s new Optimer+ affinity ligand platform in development of their pipeline of ’EM’ molecules that specifically target pathways involved in transplant rejection.’

This approach will improve transplant access for ‘difficult to transplant patients’ and improve the chances of transplant success, Aptamer said.

In addition, EM molecules will be used for transplant monitoring.

Aptamer said that these treatments are targeting a £800 million transplant diagnostic sector and a potential £2 billion transplant immunotherapy market.

Aptamer Chief Technical Officer Arron Tolley said: ‘We’re delighted to bring our proprietary Optimer+ platform to support Kairos Biotech in this game-changing theranostic application. Initial animal studies have shown the Optimer+ binders to be well tolerated for therapeutic approaches, and the exquisite specificity of these binders is ideally suited to such a large-scale diagnostic and therapeutic project. The team at Kairos has an exciting scientific approach to immunosuppression that could offer an improved outlook for transplant patients, and we look forward to working with them to advance this using Optimer+.’

Shares in Aptamer were up 4.8% at 0.55 pence each in London on Thursday midday.

Copyright 2024 Alliance News Ltd. All Rights Reserved.